ATANASIO
PANDIELLA ALONSO
Investigador
Universitat Autònoma de Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Universitat Autònoma de Barcelona (5)
2022
-
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer
Cancer research, Vol. 82, Núm. 24, pp. 4670-4679
2017
-
Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer
Clinical Cancer Research, Vol. 23, Núm. 22, pp. 7006-7019
-
Resistance to the antibody–drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity
Cancer Research, Vol. 77, Núm. 17, pp. 4639-4651
2014
-
Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy
Journal of the National Cancer Institute, Vol. 106, Núm. 11
2013
-
A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers
Oncogene, Vol. 32, Núm. 11, pp. 1452-1459